Compare Gilead Sciences, Inc. (GILD) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Marvell Technology Inc — how do they compare? Gilead Sciences, Inc. trades at $137 (market cap $168.35B), while Marvell Technology Inc trades at $222.75 (market cap $190.56B). The key difference: Gilead Sciences, Inc. and Marvell Technology Inc are close in size by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GILD | MRVL | |
|---|---|---|
Market Cap | $168.35B | $190.56B |
Sector | Health | Technology |
52-Week High | $155.80 | $316.43 |
52-Week Low | $110.56 | $62.31 |
Enterprise Value | $191.42B | $191.99B |
Dividend Yield | 2.42% | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Marvell Technology (MRVL) trades at $208.56, down 4.65% on the day, amid a broader semiconductor sell-off. The stock shows a bullish technical signal with support near $201 and resistance at $223. Fundamentally, while recent quarters have seen EPS beats, the company reported a net loss of $885 million for 2025, though revenue grew to $5.77 billion. Analyst sentiment remains strongly positive with an 82% buy rating and a $275.68 consensus price target, citing AI infrastructure growth drivers.
The outlook for MRVL is supported by its positioning in AI data center and optical networking markets, with partnerships like NVIDIA and Microsoft's Maia 300 offering significant upside. Key risks include intense competition, margin pressures, and geopolitical supply chain disruptions. Investors should weigh the high valuation multiples against the potential for AI-driven revenue acceleration in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
